MS4A1 and cancer: The low rate of apparent loss-of-function mutations of MS4A1, including nonsense and frameshift mutations or gene fusions (<1% of TCGA pan-cancer total of 10437 samples) cannot fully account for such as major discrepancies between CD20 protein expressions and full-length MS4A1 mRNA expressions in tumors.